Nature Medicine最新文献

{"title":"Using a sex- and gender-informed lens to enhance care in Parkinson’s disease","authors":"Laura Castro-Aldrete, Marie Huc, Josefa Domingos, Elisabetta Vaudano, Martin Klietz, Claudia Trenkwalder, Annelien Oosterbaan, Richelle Flanagan, Roberta Marongiu, Antonella Santuccione-Chadha","doi":"10.1038/s41591-024-03363-2","DOIUrl":"https://doi.org/10.1038/s41591-024-03363-2","url":null,"abstract":"Sex and gender differences in Parkinson’s disease should be a priority for researchers and clinicians, to ensure appropriate care is provided to patients.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"27 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial","authors":"Jessica S. W. Borgers, Divya Lenkala, Victoria Kohler, Emily K. Jackson, Matthijs D. Linssen, Sebastian Hymson, Brian McCarthy, Elizabeth O’Reilly Cosgrove, Kristen N. Balogh, Ekaterina Esaulova, Kimberly Starr, Yvonne Ware, Sebastian Klobuch, Tracey Sciuto, Xi Chen, Gauri Mahimkar, Joong Hyuk F. Sheen, Suchitra Ramesh, Sofie Wilgenhof, Johannes V. van Thienen, Karina C. Scheiner, Inge Jedema, Michael Rooney, Jesse Z. Dong, John R. Srouji, Vikram R. Juneja, Christina M. Arieta, Bastiaan Nuijen, Claudia Gottstein, Olivia C. Finney, Kelledy Manson, Cynthia M. Nijenhuis, Richard B. Gaynor, Mark DeMario, John B. Haanen, Marit M. van Buuren","doi":"10.1038/s41591-024-03418-4","DOIUrl":"https://doi.org/10.1038/s41591-024-03418-4","url":null,"abstract":"<p>New treatment approaches are warranted for patients with advanced melanoma refractory to immune checkpoint blockade (ICB) or BRAF-targeted therapy. We designed BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, and tested this in a 3 + 3 dose-finding study with two dose levels (DLs) in patients with locally advanced or metastatic melanoma, disease progression after ICB, measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1) and, where appropriate, BRAF-targeted therapy. Primary and secondary objectives were evaluation of safety, highest tolerated dose and anti-tumor activity. We report here the non-pre-specified, final results of the completed monotherapy arm consisting of nine patients: three at DL1 (1 × 10⁸–1 × 10⁹ cells) and six at DL2 (2 × 10⁹–1 × 10¹⁰ cells). Drug products (DPs) were generated for all enrolled patients. BNT221 was well tolerated across both DLs, with no dose-limiting toxicities of grade 3 or higher attributed to the T cell product observed. Specifically, no cytokine release, immune effector cell-associated neurotoxicity or macrophage activation syndromes were reported. A dose of 5.0 × 10⁸–1.0 × 10¹⁰ cells was identified for further study conduct. Six patients showed stable disease as best overall response, and tumor reductions (≤20%) were reported for four of these patients. In exploratory analyses, multiple mutant-specific CD4⁺ and CD8⁺ T cell responses were generated in each DP. These were cytotoxic, polyfunctional and expressed T cell receptors with broad functional avidities. Neoantigen-specific clonotypes were detected after treatment in blood and tumor. Our results provide key insights into this neoantigen-specific adoptive T cell therapy and demonstrate proof of concept for this new therapeutic approach. ClinicalTrials.gov registration: NCT04625205.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"367 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142917020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir","authors":"M. Ali Rai, Jana Blazkova, Lela Kardava, Jesse S. Justement, Victoria Shi, Maegan R. Manning, Aniqa Shahid, Winnie Dong, Brooke D. Kennedy, Adeline B. Sewack, Jeanette Higgins, Clarisa M. Buckner, Kathleen Gittens, Raymond E. West, Aaron S. Devanathan, Ralph Mangusan, Kathryn Lurain, Ramya Ramaswami, Robert Yarchoan, Michael C. Sneller, Alice K. Pau, Zabrina L. Brumme, Susan Moir, Tae-Wook Chun","doi":"10.1038/s41591-024-03357-0","DOIUrl":"https://doi.org/10.1038/s41591-024-03357-0","url":null,"abstract":"<p>The clinical management of people with multidrug-resistant (MDR) human immunodeficiency virus (HIV) remains challenging despite continued development of antiretroviral agents. A 58-year-old male individual with MDR HIV and Kaposi sarcoma (KS) was treated with a new antiretroviral regimen consisting of anti-CD4 domain 1 antibody UB-421 and capsid inhibitor lenacapavir. The individual experienced delayed but sustained suppression of plasma viremia and a substantial increase in the CD4⁺ T cell count. A longitudinal examination of plasma HIV and infectious isolates showed no evidence of viral evolution or the emergence of UB-421- or lenacapavir-resistant viruses. The individual received three cycles of liposomal doxorubicin and five doses of anti-programmed cell death protein 1 (PD-1) monoclonal antibody pembrolizumab that resulted in improvement in KS with flattening of lesions. Our data demonstrate that combination therapy with UB-421 could provide sustained virologic suppression in people harboring MDR HIV with limited therapeutic alternatives.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"27 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Setting sights on a single-shot malaria vaccine","authors":"Debashree Goswami,&nbsp;Stefan H. I. Kappe","doi":"10.1038/s41591-024-03427-3","DOIUrl":"10.1038/s41591-024-03427-3","url":null,"abstract":"In a game-changing development for malaria vaccines, single-dose immunization with a genetically weakened whole malaria parasite vaccine achieved an unprecedented 90% protection.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"31 1","pages":"33-34"},"PeriodicalIF":58.7,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","authors":"Anna M. Varghese, Maria A. Perry, Joanne F. Chou, Subhiksha Nandakumar, Daniel Muldoon, Amanda Erakky, Amanda Zucker, Christopher Fong, Miika Mehine, Bastien Nguyen, Olca Basturk, Fiyinfolu Balogun, David P. Kelsen, A. Rose Brannon, Diana Mandelker, Efsevia Vakiani, Wungki Park, Kenneth H. Yu, Zsofia K. Stadler, Mark A. Schattner, William R. Jarnagin, Alice C. Wei, Debyani Chakravarty, Marinela Capanu, Nikolaus Schultz, Michael F. Berger, Christine A. Iacobuzio-Donahue, Chaitanya Bandlamudi, Eileen M. O’Reilly","doi":"10.1038/s41591-024-03362-3","DOIUrl":"https://doi.org/10.1038/s41591-024-03362-3","url":null,"abstract":"<p>Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by <i>KRAS</i> exon 2 mutations. Most patients with PDAC present with advanced disease and are treated with cytotoxic therapy. Genomic biomarkers prognostic of disease outcomes have been challenging to identify. Herein leveraging a cohort of 2,336 patients spanning all disease stages, we characterize the genomic and clinical correlates of outcomes in PDAC. We show that a genomic subtype of <i>KRAS</i> wild-type tumors is associated with early disease onset, distinct somatic and germline features, and significantly better overall survival. Allelic imbalances at the <i>KRAS</i> locus are widespread. <i>KRAS</i> mutant allele dosage gains, observed in one in five (20%) <i>KRAS</i>-mutated diploid tumors, are correlated with advanced disease and demonstrate prognostic potential across disease stages. With the rapidly expanding landscape of <i>KRAS</i> targeting, our findings have potential implications for clinical practice and for understanding de novo and acquired resistance to RAS therapeutics.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"29 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resurgence of malaria and artemisinin resistance in Africa requires a concerted response","authors":"Nebiyu Dereje, Mosoka Papa Fallah, Tamrat Shaweno, Alemayehu Duga, Mazyanga Lucy Mazaba, Tajudeen Raji, Morenike O. Folayan, Ngashi Ngongo, Nicaise Ndembi, Jean Kaseya","doi":"10.1038/s41591-024-03439-z","DOIUrl":"https://doi.org/10.1038/s41591-024-03439-z","url":null,"abstract":"<p>Malaria is one of the leading causes of morbidity and mortality globally, with an estimated 249 million cases and 608,000 deaths in 2022, of which 94% and 95% occurred in Africa, respectively¹. As a result of innovative public health measures, malaria-related mortality in Africa has decreased dramatically, from 808,000 deaths in 2000 to 580,000 in 2022 (ref. ¹). Nine African countries have already eradicated malaria including five North African countries (Egypt, Libya, Tunisia, Algeria and Morocco) and a few sub-Saharan countries (Lesotho, Mauritius, Seychelles and Cabo Verde)². The introduction and scale-up of malaria vaccines could enhance global malaria elimination efforts.</p><p>However, in recent years, the continent has faced a resurgence of malaria, alongside the alarming emergence of artemisinin resistance, which threatens to undermine decades of progress. The effectiveness of ongoing malaria prevention programs is threatened by climate change, the emergence of insecticide and drug-resistant strains, and new variants of mosquitos. Emerging and reemerging public health emergencies (such as mpox and Marburg virus outbreaks) and armed conflicts in Africa have worsened malaria program effectiveness by interrupting the continuity of essential health services, distracting political and public health leadership, and requiring the diversion of limited public health resources.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"80 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142917025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial","authors":"Geert V. T. Roozen,&nbsp;Roos van Schuijlenburg,&nbsp;Annefleur D. O. Hensen,&nbsp;Jan Pieter R. Koopman,&nbsp;Olivia A. C. Lamers,&nbsp;Fiona J. A. Geurten,&nbsp;Jeroen C. Sijtsma,&nbsp;Els Baalbergen,&nbsp;Jacqueline J. Janse,&nbsp;Séverine Chevalley-Maurel,&nbsp;Chanel M. Naar,&nbsp;Sascha Bezemer,&nbsp;Hans Kroeze,&nbsp;Huybert J. F. van de Stadt,&nbsp;Bram de Visser,&nbsp;Pauline Meij,&nbsp;Mara S. Tihaya,&nbsp;Emil Colstrup,&nbsp;Eva Iliopoulou,&nbsp;Helena M. de Bes-Roeleveld,&nbsp;Els Wessels,&nbsp;M. Y. Eileen C. van der Stoep,&nbsp;Chris J. Janse,&nbsp;Rajagopal Murugan,&nbsp;Blandine M. D. Franke-Fayard,&nbsp;Meta Roestenberg","doi":"10.1038/s41591-024-03347-2","DOIUrl":"10.1038/s41591-024-03347-2","url":null,"abstract":"Malaria vaccines consisting of metabolically active Plasmodium falciparum (Pf) sporozoites can offer improved protection compared with currently deployed subunit vaccines. In a previous study, we demonstrated the superior protective efficacy of a three-dose regimen of late-arresting genetically attenuated parasites administered by mosquito bite (GA2-MB) compared with early-arresting counterparts (GA1-MB) against a homologous controlled human malaria infection. Encouraged by these results, we explored the potency of a single GA2-MB immunization in a placebo-controlled randomized trial. Primary outcomes were safety and tolerability, time-to-parasitemia and protective efficacy. Humoral and cellular immunological results were considered secondary outcomes. Here we report the safe administration of GA2-MB with no breakthrough malaria and sterile protection in nine of ten participants at 6 weeks after a single immunization with 50 GA2-infected mosquitoes, compared with none of five mock-immunized participants, against a homologous controlled human malaria infection. Immunization increased circulating Pf-specific polyfunctional effector memory CD4+ T cells coexpressing tumor necrosis factor and interleukin-2. This unprecedented 90% protective efficacy after a single low-dose immunization holds great promise for the potency of GA2 immunization. Future studies should demonstrate whether GA2 is similarly efficacious in pre-exposed populations and whether the favorable safety profile reported here holds up in larger groups. ClinicalTrials.gov registration: NCT05468606 . In a small randomized controlled clinical trial, a single immunization for malaria using mosquitoes infected with attenuated parasites showed unprecedented 90% protective efficacy and did not lead to breakthrough disease.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"31 1","pages":"218-222"},"PeriodicalIF":58.7,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41591-024-03347-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of conditional cash transfers on tuberculosis incidence and mortality according to race, ethnicity and socioeconomic factors in the 100 Million Brazilian Cohort","authors":"Gabriela S. Jesus, Priscila F.P.S. Gestal, Andrea F. Silva, Daniella M. Cavalcanti, Iracema Lua, Maria Yury Ichihara, Mauricio L. Barreto, Delia Boccia, Mauro N. Sanchez, Davide Rasella","doi":"10.1038/s41591-024-03381-0","DOIUrl":"https://doi.org/10.1038/s41591-024-03381-0","url":null,"abstract":"<p>Conditional cash transfer (CCT) programs have been implemented globally to alleviate poverty. Although tuberculosis (TB) is closely linked to poverty, the effects of CCT on TB outcomes among populations facing social and economic vulnerabilities remain uncertain. Here we estimated the associations between participation in the world’s largest CCT program, the Brazilian Bolsa Família Program (BFP), and the reduction of TB incidence, mortality and case-fatality rates using the nationwide 100 Million Brazilian Cohort between 2004 and 2015. We also evaluated these relationships according to race, ethnicity, wealth levels, sex and age. Exposure to the BFP was associated with a large reduction in TB incidence (adjusted rate ratio (aRR): 0.59; 95% confidence interval (CI): 0.58–0.60) and mortality (aRR: 0.69; 95% CI: 0.65–0.73). The strongest BFP association was observed in individuals of Indigenous ethnicity both for TB incidence (aRR: 0.37; 95% CI: 0.32–0.42) and mortality (aRR: 0.35; 95% CI: 0.20–0.62), and in individuals of Black and Pardo ethnicity (incidence—aRR: 0.58; 95% CI: 0.57–0.59; mortality—aRR: 0.69; 95% CI: 0.64–0.73). BFP associations were considerably stronger among individuals living in extreme poverty both for TB incidence (aRR: 0.49; 95% CI: 0.49–0.50) and mortality (aRR: 0.60; 95% CI: 0.55–0.65). CCT can strongly reduce TB incidence and mortality in individuals living in extreme poverty, and of Indigenous, Black and Pardo ethnicity, and could significantly contribute to achieving the End TB Strategy targets and TB-related Sustainable Development Goals.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"1 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large floods drive changes in cause-specific mortality in the United States","authors":"Victoria D. Lynch, Jonathan A. Sullivan, Aaron B. Flores, Xicheng Xie, Sarika Aggarwal, Rachel C. Nethery, Marianthi-Anna Kioumourtzoglou, Anne E. Nigra, Robbie M. Parks","doi":"10.1038/s41591-024-03358-z","DOIUrl":"https://doi.org/10.1038/s41591-024-03358-z","url":null,"abstract":"<p>Flooding greatly endangers public health and is an urgent concern as rapid population growth in flood-prone regions and more extreme weather events will increase the number of people at risk. However, an exhaustive analysis of mortality following floods has not been conducted. Here we used 35.6 million complete death records over 18 years (2001–2018) from the National Center for Health Statistics in the United States, highly resolved flood exposure data and a Bayesian conditional quasi-Poisson model to estimate the association of flooding with monthly county-level death rates for cancers, cardiovascular diseases, infectious and parasitic diseases, injuries, neuropsychiatric conditions and respiratory diseases up to 3 months after the flood. During the month of flooding, very severe heavy rain-related floods were associated with increased infectious disease (3.2%; 95% credible interval (CrI): 0.1%, 6.2%) and cardiovascular disease (2.1%; 95% CrI: 1.3%, 3.0%) death rates and tropical cyclone-related floods were associated with increased injury death rates (15.3%; 95% CrI: 12.4%, 18.1%). During the month of very severe tropical cyclone-related flooding, increases in injury death rate were higher for those ≥65 years old (24.9; 95% CrI: 20.0%, 29.8%) than for those aged &lt;65 years (10.2%; 95% CrI: 6.6%, 13.8%) and for females (21.2%; 95% CrI: 16.3%, 26.1%) than for males (12.6%; 95% CrI: 9.1%,16.1%). Effective public health responses are critical now and with projected increased flood severity driven by climate change.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"4 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic changes upon treatment with semaglutide in individuals with obesity","authors":"Lasse Maretty,&nbsp;Dipender Gill,&nbsp;Lotte Simonsen,&nbsp;Keng Soh,&nbsp;Loukas Zagkos,&nbsp;Michael Galanakis,&nbsp;Jonas Sibbesen,&nbsp;Miquel Triana Iglesias,&nbsp;Anna Secher,&nbsp;Dirk Valkenborg,&nbsp;Jonathan Q. Purnell,&nbsp;Lotte Bjerre Knudsen,&nbsp;Abd A. Tahrani,&nbsp;Milan Geybels","doi":"10.1038/s41591-024-03355-2","DOIUrl":"10.1038/s41591-024-03355-2","url":null,"abstract":"Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 (n = 1,311) and STEP 2 (n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways. Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering. A comparison of semaglutide with real-world proteomic profiles revealed potential benefits on disease-specific proteomic signatures including the downregulation of specific proteins associated with cardiovascular disease risk, supporting its reported effects of lowering cardiovascular disease risk and potential drug repurposing opportunities. This study showcases the potential of proteomics data gathered from randomized trials for providing insights into disease mechanisms and drug repurposing opportunities. These data also highlight the unmet need for, and importance of, examining proteomic changes in response to weight loss pharmacotherapy in future trials. Using serum samples collected from participants of the STEP 1 and STEP 2 trials, the authors have uncovered changes to the proteome upon semaglutide treatment, which can shed light on the mechanism of action of the drug driving its benefits in obesity-related conditions.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"31 1","pages":"267-277"},"PeriodicalIF":58.7,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41591-024-03355-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}